$TECX

Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) • U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investig

Tectonic Therapeutic (TECX) reported Q2 results, highlighting progress in two clinical trials, TX45 for pulmonary hypertension and TX2100 for a rare bleeding disorder. The company has sufficient cash to fund operations into 2029. Net loss widened to $22.3M from $20M a year earlier. Hedge fund ownership increased, while short interest remains high at 17.86% of the float.

Analysts reiterated Buy ratings on Amgen (AMGN), Tectonic Therapeutic (TECX), and Revolution Medicines (RVMD). Amgen has a $394.73 avg. price target, Tectonic $79.50, and Revolution $241.70. Analysts cited in reports include Matt Phipps, Uy Ear, and Laura Prendergast.

Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights • Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-

Biotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG

Tectonic Therapeutic (NASDAQ: TECX) said it completed enrollment in its 24-week APEX Phase 2 trial of TX45 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The trial enrolled 191 patients in 14 countries, with ~72% in CpcPH patients (PVR >3 WU). Topline results are expected in early Q1 2027.

Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001681087 0001681087 2026-06-08 2026-06-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2

WATERTOWN, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Tectonic Therapeutic, Inc. ( NASDAQ: TECX ) ( "Tectonic" ) , a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ( ...

WATERTOWN, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Tectonic Therapeutic, Inc. TECX ( "Tectonic" ) , a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ( GPCRs ) , today ...

WATERTOWN, Mass., May 17, 2025 ( GLOBE NEWSWIRE ) -- Tectonic Therapeutic, Inc. ( NASDAQ: TECX ) ( "Tectonic" ) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection ...